Description
EMPA-M 12.5/1000 tablets provide a powerful combination therapy for adults with type 2 diabetes. Each tablet contains 12.5mg of Empagliflozin and 1000mg of Metformin Hydrochloride. Empagliflozin, an SGLT2 inhibitor, works by helping your kidneys excrete excess glucose from the body through urine, thereby lowering blood sugar. Metformin, a biguanide, reduces glucose production in the liver and improves the body’s sensitivity to insulin. This dual-action approach not only effectively controls blood sugar levels but also offers significant cardiovascular benefits by reducing the risk of heart-related death and hospitalization for heart failure, as well as slowing the progression of chronic kidney disease. Used alongside diet and exercise, EMPA-M 12.5/1000 offers comprehensive support for overall diabetes management.
